Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03702725 · OUTCOME

Duration of Response

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma · Source last updated 2026-01-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
months
Interval / dispersion
Not reported
Time frame
34 Months

What was measured

The duration of response is the time from initiation of first response to first documentation of disease progression or death. Patients who have not progressed will be censored at the date of their last disease evaluation.

Analysis population: All eligible patients who met IMWG criteria for CR, VGPR, or PR on two consecutive evaluations at least 4 weeks apart

Groups in this outcome

Dose Level 1 (Starting DL)

Ibrutinib 560 mg on Days 1-28,\> Lenalidomide 15 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\> \> Every 28 days

Dose Level 2

Ibrutinib 560 mg on Days 1-28,\> Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\> \> Every 28 days

Dose Level 3

Ibrutinib 840 mg on Days 1-28,\> Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\> \> Every 28 days

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Level 1 (Starting DL)1
Dose Level 20
Dose Level 31

Reported measurements

Source class 1
Values in months · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dose Level 1 (Starting DL)7.1Not reportedNot reportedNot reportedNot reported
Dose Level 33.1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        7.1
      2. group Id
        OG002
        value
        3.1
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    2. group Id
      OG001
      value
      0
    3. group Id
      OG002
      value
      1
    units
    Participants
description
The duration of response is the time from initiation of first response to first documentation of disease progression or death. Patients who have not progressed will be censored at the date of their last disease evaluation.
groups
  1. description
    Ibrutinib 560 mg on Days 1-28,\> Lenalidomide 15 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\> \> Every 28 days
    id
    OG000
    title
    Dose Level 1 (Starting DL)
  2. description
    Ibrutinib 560 mg on Days 1-28,\> Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\> \> Every 28 days
    id
    OG001
    title
    Dose Level 2
  3. description
    Ibrutinib 840 mg on Days 1-28,\> Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\> \> Every 28 days
    id
    OG002
    title
    Dose Level 3
param Type
NUMBER
population Description
All eligible patients who met IMWG criteria for CR, VGPR, or PR on two consecutive evaluations at least 4 weeks apart
reporting Status
POSTED
time Frame
34 Months
title
Duration of Response
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice